Industry news that matters to you.  Learn more

Critical Health Unveils a Biomarker for Diabetic Retinopathy Progression at the EuRetina Congress in Paris

Reading time: 2 – 4 minutes

Critical Health, a provider of innovative decision support software for ophthalmology, will showcase at the EuRetina Congress in Paris, France (Booth 222B). Recently granted a European IT Excellence Award, Retmarker allows physicians to have a more precise source of information, which is not prone to errors related to the complexity in the estimations of lesion areas present in each subfield of the retinography (color fundus photograph).

Retmarker was developed in close partnership with AIBILI (Association for Innovationa and Biomedical Research on Light and Image). Using advanced proprietary algorithms, RetmarkerDR monitors the progression of Diabetic Retinopathy, helping ophthalmologists to detect and calculate the formation and disappearance rates of microaneurysms in the retina. Microaneurysms Rates are key indicators of Diabetic Retinopathy progression, a disease that is the highest growing cause of preventable blindness in developed countries.

RetmarkerDR is backed by leading edge research on Microaneurysm Turnover done by AIBILI (the new and most reliable biomarker of Diabetic Retinopathy progression using non-invasive imaging methods).

“According to our research, where we analysed different type 2 diabetic patients with nonproliferative retinopathy, Microaneurysm Turnover was a key factor for the classification in different phenotypes and appears to be a good predictor of progression to Clinically Significant Macular Edema (CSME),” stated Professor Conceição Lobo, lead ophthalmologist and researcher at University Hospital of Coimbra, Portugal.

Ricardo Cunha-Vaz, Critical Health’s CEO, states “RetmarkerDR software solution is a breakthrough in predicting Diabetic Retinopathy progression from a Nonproliferative stage to Clinically Significant Macular Edema (CSME), a sight-threatening stage”.

To be showcased for the first time at EuRetina is RetmarkerAMD Research, a new software solution under development which enables computer-assisted marking of digital images from patients with Age-related Macular Degeneration (AMD), the main cause of blindness in persons over 50 in developed countries. On the other hand, RetmarkerC enables the detection of changes in the retina over time which can be due to several pathologies. Also at the 10th EuRetina Congress, Prof. José Cunha-Vaz from Critical Health’s partner AIBILI will be presenting a paper, on Main Session 1 “Research in Retinal Imaging ”, entitled “Digital Imaging of the Eye Fundus. New approaches”. On September 2nd, on Main Session 3 “Imaging to Monitor Progression”, he will present a paper on “Computer-Assisted monitoring of retinal diseases”. On the day after, Professor José Cunha-Vaz will take part on Course 4 of the Instructional courses on “New and future diagnostic tools for retinal diseases”, to be followed, in the afternoon, by the presentation of the study “Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures” at the EVICR.net Retina Session.

Source: Critical Health